BECN2 Research Linked Receptor Recycling to Cannabinoid Tolerance in Mice

Receptor loss and receptor recycling can affect continued cannabinoid responses. Research on BECN2 linked a cellular trafficking mechanism with tolerance in mice, but it did not establish a consumer strategy for preventing cannabis tolerance.

A pathway connecting cells and behavior

The supplied abstract describes BECN2 as participating in regulation of CB1 receptor recycling and resensitization after prolonged agonist exposure. The investigators combined molecular work with a mouse genetic model and repeated-cannabinoid behavioral testing.

The intervention concerned a specific mechanism

Becn2 deletion preserved receptor activity and reduced analgesic tolerance in the reported model. Selected autophagy-inducing interventions also affected the interaction between BECN2 and GPRASP1, with corresponding effects on receptor levels, signaling and mouse tolerance.

Autophagy is not one universal treatment

A biological pathway can have different consequences depending on the cell, timing and intervention. Evidence that particular experimental manipulations altered receptor handling does not show that any supplement, diet or activity marketed as promoting autophagy reproduces the effect.

The result also concerns tolerance to selected antinociceptive effects rather than a comprehensive measurement of intoxication, dependence or safety. Mouse brain receptor findings cannot identify whether an individual driver was impaired. The study supports a mechanistic research direction while leaving human effectiveness, adverse effects and appropriate clinical use unanswered. Descriptions should name the actual manipulation instead of converting the pathway into an untested wellness recommendation.

Related: interpreting cannabis tolerance claims.

Research cited

Kuramoto K; Wang N; Fan Y; Zhang W; Schoenen FJ; Frankowski KJ; Marugan J; Zhou Y; Huang S; He C. Autophagy activation by novel inducers prevents BECN2-mediated drug tolerance to cannabinoids. Autophagy (2016). doi:10.1080/15548627.2016.1187367. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A 2026 Cannabis Review Explains Why Potency, Placebo Response and Sedation Need Separate Measures

A 2026 narrative review argues that product potency is not the same as delivered THC dose and that placebo responses remain important among experienced users. Its laboratory framework also distinguishes reduced drug reinforcement from nonspecific sedation. Users can change how they inhale The review notes that participants alter inhalation patterns…

Spread the love

Read Article: A 2026 Cannabis Review Explains Why Potency, Placebo Response and Sedation Need Separate Measures

THC Antinociception Persisted Without the Same Dynorphin Signal in Tolerant Rats

A 1999 rat study found that tolerance weakened THC-related modulation of spinal dynorphin, while antinociception could still occur without the same elevated dynorphin measure. The role of a downstream signal changed with dose and adaptive state. The experiment examined spinal responses The work followed earlier findings linking acute intrathecal THC…

Spread the love

Read Article: THC Antinociception Persisted Without the Same Dynorphin Signal in Tolerant Rats

A Passiflora-Derived Fraction Reduced THC Withdrawal Signs in a Mouse Model

A 2002 mouse experiment reported fewer antagonist-precipitated withdrawal signs with a Passiflora-derived benzoflavone fraction. The finding concerns a defined experimental preparation and animal model, not a demonstrated treatment for cannabis-use disorder in people. Concurrent and acute interventions were tested Mice received repeated oral THC with or without the fraction. A…

Spread the love

Read Article: A Passiflora-Derived Fraction Reduced THC Withdrawal Signs in a Mouse Model

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us